Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.

MLA

van der Wall, Sake J., et al. “Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.” HemaSphere, vol. 2, no. 1, Feb. 2018, p. e19. EBSCOhost, https://doi.org/10.1097/HS9.0000000000000019.

APA

van der Wall, S. J., Klok, F. A., den Exter, P. L., Barrios, D., Morillo, R., Cannegieter, S. C., Jimenez, D., & Huisman, M. V. (2018). Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism. HemaSphere, 2(1), e19. https://doi.org/10.1097/HS9.0000000000000019

Chicago

van der Wall, Sake J, Frederikus A Klok, Paul L den Exter, Deisy Barrios, Raquel Morillo, Suzanne C Cannegieter, David Jimenez, and Menno V Huisman. 2018. “Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.” HemaSphere 2 (1): e19. doi:10.1097/HS9.0000000000000019.